This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image

SANCUSO®

SANCUSO®

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Click here for prescribing information and adverse event reporting.

Resources

Information and resources for the management of patients who have been prescribed SANCUSO in the United Kingdom or Northern Ireland.

Patient Information Leaflet (UK)

Patient Information Leaflet (NI)

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    KKI/UK/IM-M1/0001 November 2023